Andrew C. Chan - 23 Apr 2026 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director
Issuer ticker: CRVS
Reported as of: 23 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Apr 2026, 17:32:20 UTC
Source filing: View source filing
Reporting owner signature: /s/ Leiv Lea, as Attorney-in-Fact for Andrew C. Chan

Key filing fact

Andrew C. Chan filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 27 Apr 2026.

Key facts

This page summarizes Andrew C. Chan's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Apr 2026, 17:32.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002131504 Primary reporting owner

Chan Andrew C.

Relationship: Director
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Leiv Lea, as Attorney-in-Fact for Andrew C. Chan
Signature date: 27 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 23 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $16.02
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 23, 2026, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.